Essure has been marketed as a permanent sterilization method for women that does not require surgery. Essure was first developed by Conceptus Inc., which became part of Bayer Healthcare in 2013. The Essure device is a pair of soft, flexible metal and fiber coils that are inserted into the fallopian tubes by a healthcare provider.
After a period of three months, scar tissue forms around the Essure implant, creating a barrier that prevents sperm from reaching the ova so that the woman is unable to conceive.
The Essure Claims Foundation is an independent Dutch foundation (the “Foundation”). The Foundation stands up for the interests of injured women who have suffered damage from implantation of the Essure device.
The Foundation looks after and represents women who suffer damage, are at risk of suffering damage and/or have suffered damage as a result of Bayer's actions and/or omissions with regard to the Essure implant.
The Foundation seeks to achieve its goals by conducting research and providing information. The Foundation also intends to initiate legal proceedings in the Netherlands on behalf of injured women and to request a declaration of law that establishes Bayer's unlawful conduct against the victims. The Foundation strives to achieve a binding settlement with Bayer that compensates the injured women. The Foundation is also investigating other ways to ensure that the disadvantaged women are compensated.
Since Essure has been put on the market, there has been an increasing number of reports of dangerous side effects associated with Essure. Many women have experienced unwanted side effects due to Essure, including perforation of the uterus or other organs and chronic pain. Many of these women had to have the Essure implant surgically removed.
On May 29, 2017, Bayer announced the removal of Essure from the Dutch market, after which sales and distribution were discontinued as of July 1, 2017. After thousands of complaints worldwide against Bayer, on September 25, 2017, it stopped sales and distribution in all countries outside the United States. On December 31, 2018, Bayer stopped marketing Essure in the United States.